Table 1.
E-C coupling–related myopathies | Main clinical features | Fiber phenotype | Causative genes | Inheritance | Mechanism (RyR1 channel) |
---|---|---|---|---|---|
CCD | ✓ Infantile nonprogressive hypotonia and motor development delay ✓ Mild proximal muscle weakness ✓ Respiratory distress ✓ High arched palate ✓ Craniofacial dysmorphism |
✓ Centrally located, well-demarcated cores, spanning the whole fiber axis ✓ Predominance in type 1 fibers ✓ Increased central nuclei |
RYR1 >90% | AD or AR | GoF, LoF |
MYH7 | AD | Altered assembly and function of myosin dimers | |||
MmD | ✓ Axial muscle weakness, scoliosis, respiratory insufficiency, and limb joint hyperlaxity ✓ Ophthalmoplegia ✓ Arthrogryposis ✓ Hand amyotrophy |
✓ Numerous cores in a limited area on longitudinal section ✓ Multiple internally located nuclei ✓ Predominance in type 1 fibers |
RYR1 ∼20% (homozygosity or compound heterozygosity) | AR | GoF, LoF, lower protein levels |
SEPN1 ∼50% | AR | Altered redox activity | |||
TTN (homozygosity or compound heterozygosity) | AR | M-line alteration | |||
MYH7 | AD | Not defined | |||
ACTA1 | AR | Not defined | |||
MEGF10 | AD or AR | Not defined | |||
CACNA1S | AD | Lower protein levels | |||
CNM | ✓ Not progressive proximal muscle weakness ✓ Not progressive hypotonia |
✓ Centralized and internalized nuclei ✓ Peripheral halos depleted of oxidative activity ✓ Cores |
RYR1 ∼15% (compound heterozygosity) | AR | Lower protein levels |
MTM1 | XLR | Altered vesicle trafficking | |||
DNM2 | AD | Altered membrane fission | |||
BIN1 | AD | Altered membrane tubulation | |||
TTN | AR | M-line alterations | |||
SPEG | AR | Altered interaction with MTM1 and desmin | |||
CFTD | ✓ Static or slowly progressive muscle weakness ✓ Respiratory and proximal axial weakness ✓ Ophthalmoplegia ✓ Dysphagia ✓ Facial muscle weakness |
✓ Fiber size disproportion (35–40% of type 1 fibers are smaller in size than type 2 fibers) ✓ Age-related development of rods, cores, and central nuclei |
RYR1 ∼20% | AR | Lower protein levels |
ACTA1 | AD | Altered interaction with TPM | |||
TPM2 | AD or AR | Altered interaction with actin | |||
TPM3 | AD or AR | Altered interaction with actin | |||
SEPN1 | AR | Altered redox activity | |||
MYH7 | AD | LoF, altered interaction with myosin binding protein | |||
LMNA | AD | Not defined | |||
ZAK | AR | LoF | |||
SPEG | AR | LoF | |||
DuCD | ✓ Ocular involvement (eyelid ptosis, ophthalmoplegia) | ✓ Irregularly sized/shaped “dusty” cores (reddish-purple granular material deposition) spanning 10–50 sarcomeres ✓ Myofibrillar disorganization |
RYR1 | AR | Lower protein levels |
CRM | ✓ Nonspecific clinical features, including hypotonia, muscle weakness, scoliosis, and respiratory insufficiency | ✓ Nemaline bodies (rods), clustered or widely distributed along the fibers ✓ Central cores |
RYR1 | AD or AR | GoF, LoF |
CFL2 | AR | Protein misfolding and degradation | |||
ACTA1 | AD | Altered stability or function | |||
TPM3 | AD or AR | Not defined | |||
NEB | AR | Not defined | |||
MH | ✓ Muscle rigidity and cardiac arrhythmia, occurring only following exposure to succinylcholine and volatile anesthetics ✓ Sustained contractures, ✓ Hyperthermia ✓ Hyperkalemia ✓ Hypermetabolism |
✓ No histological features can be found in muscle fibers from MH patients | RYR1 | AD | GoF |
CACNA1S | AD | GoF | |||
SOCE-related myopathies | |||||
TAM/Stormorken syndrome | ✓ Muscle weakness ✓ Myalgia ✓ Cramps ✓ Increased creatine kinase levels ✓ Exercise intolerance |
✓ Single- or double-walled SR tubules arranged as honeycomb-like structures in type 2 fibers ✓ Prevalence of type 1 fibers |
STIM1 | AD | GoF |
ORAI | AD | GoF | |||
CASQ1 | AD | Altered polymerization | |||
RYR1 | AD | GoF |
Proteins encoded by the indicated genes and relative references are reported in the text. AD, autosomal dominant; AR, autosomal recessive; GoF, gain-of-function; LoF, loss-of-function; XLR, X-linked recessive.